Ketamine for Methamphetamine Use Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 11, 2024

Primary Completion Date

August 18, 2026

Study Completion Date

October 15, 2026

Conditions
Substance Use DisordersSubstance UseMethamphetamine Abuse
Interventions
DRUG

Ketamine Hydrochloride

Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.

DRUG

Midazolam Hydrochloride

Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.

Trial Locations (4)

10029

TERMINATED

Addiction Institute of Mount Sinai, New York

29617

RECRUITING

Prisma Health, Greenville

75247

RECRUITING

UT Southwestern Medical Center, Dallas

87106

RECRUITING

Interdisciplinary Substance Use and Brain Injury Facility, Albuquerque

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER